呋喃唑酮
左氧氟沙星
幽门螺杆菌
医学
养生
质子抑制剂泵
胃肠病学
阿莫西林
内科学
快速尿素酶试验
强力霉素
兰索拉唑
人口
尿素呼气试验
外科
抗生素
胃炎
幽门螺杆菌感染
微生物学
生物
环境卫生
作者
Carlos Barreda-Costa,Julio R Piccini-Larco,Lang Dai Chu-Revollar,Fernando Salazar-Muente,José A Barriga-Briceño,Madeleine Herrera-Alzamora
出处
期刊:PubMed
日期:2023-08-19
卷期号:43 (2): 116-119
被引量:1
摘要
Our objective is to determine the effectiveness of a therapeutic regimen for helicobacter pylori that includes a proton pump inhibitor, doxycycline, furazolidone and bismuth in our location. We carried out a retrospective study, non-randomized, in a private hospital in Lima, Peru. Patients with biopsy and/or rapid urease test proven helicobacter pylori infection after an endoscopy, from January 2017 to October 2022 were included. They received the therapeutic regimen of the study or an alternative triple regimen with a proton pump inhibitor, amoxicillin and levofloxacin and were followed with a urea breath test within 1 to 6 months upon completion of therapy. The quadruple therapy with furazolidone obtained success in 117/122 cases (95.9%) while the triple therapy with levofloxacin only in 5/16 (31.2%) when used for 7 days and 22/38 (57.9%) when used for 10 days, a statistically significant difference with p<0.001. Conclusion: Quadruple therapy with furazolidone reached high effectiveness in our location, while triple therapy with levofloxacin was not an acceptable alternative.
科研通智能强力驱动
Strongly Powered by AbleSci AI